| scholarly article | Q13442814 |
| P356 | DOI | 10.1126/SCIENCE.6158759 |
| P953 | full work available at URL | https://syndication.highwire.org/content/doi/10.1126/science.6158759 |
| P698 | PubMed publication ID | 6158759 |
| P2093 | author name string | D. T. Purtilo | |
| J. L. Sullivan | |||
| K. S. Byron | |||
| F. E. Brewster | |||
| P2860 | cites work | Natural cytotoxic reactivity of mouse lymphoid cells against syngeneic and allogeneic tumors. II. Characterization of effector cells | Q33901387 |
| „Natural” killer cells in the mouse. II. Cytotoxic cells with specificity for mouse Moloney leukemia cells. Characteristics of the killer cell | Q33906475 | ||
| Natural Killing of Herpes Simplex Virus Type 1-Infected Target Cells: Normal Human Responses and Influence of Antiviral Antibody | Q34093656 | ||
| Cytotoxic effector cells specific for B Cell lines transformed by Epstein-Barr virus are present in patients with infectious mononucleosis | Q35077262 | ||
| Spontaneous and antibody-dependent cell-mediated cytotoxicity by human T cell subpopulations | Q35996445 | ||
| Surface markers on human B and T lymphocytes. II. Presence of Epstein-Barr virus receptors on B lymphocytes | Q36272694 | ||
| Anti-viral activity induced by culturing lymphocytes with tumor-derived or virus-transformed cells. Identification of the anti-viral activity as interferon and characterization of the human effector lymphocyte subpopulation | Q36340292 | ||
| Mechanism of rejection of virus persistently infected tumor cells by athymic nude mice | Q36341457 | ||
| The role of natural killer cells and antibody-dependent cell-mediated cytotoxicity during murine cytomegalovirus infection | Q36343153 | ||
| Increased sensitivity of human lymphoid lines to natural killer cells after induction of the Epstein-Barr viral cycle by superinfection or sodium butyrate | Q36343407 | ||
| The beige mutation in the mouse selectively impairs natural killer cell function | Q40713185 | ||
| Spontaneous human lymphocyte-mediated cytotoxicity against tumor target cells. VII. The effect of immunodeficiency disease | Q40717877 | ||
| Role of NK cells in tumour growth and metastasis in beige mice | Q41643296 | ||
| Natural killer cells: characteristics and regulation of activity | Q42151406 | ||
| A new immunodeficiency disorder in humans involving NK cells | Q59094886 | ||
| Human Natural Killer Cell Activity is Augmented by Interferon via Recruitment of 'Pre-NK' Cells | Q66982855 | ||
| X-linked lymphoproliferative syndrome registry report | Q70646133 | ||
| P433 | issue | 4469 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | innate immune response | Q428253 |
| P304 | page(s) | 543-545 | |
| P577 | publication date | 1980-10-01 | |
| 1980-10-31 | |||
| P1433 | published in | Science | Q192864 |
| P1476 | title | Deficient natural killer cell activity in x-linked lymphoproliferative syndrome | |
| Deficient Natural Killer Cell Activity in X-Linked Lymphoproliferative Syndrome | |||
| P478 | volume | 210 |
| Q26751472 | A Bitter Sweet Symphony: Immune Responses to Altered O-glycan Epitopes in Cancer |
| Q45800510 | A non-X-linked syndrome with susceptibility to severe epstein-barr virus infections |
| Q35884890 | A quantitative ultrastructural study of peripheral blood lymphocytes containing parallel tubular arrays in Epstein-Barr virus and cytomegalovirus mononucleosis |
| Q41353152 | Activation and function of natural killer cell responses during viral infections |
| Q45805259 | Activation and role of natural killer cells in virus infections |
| Q73040812 | Acute stress impairs NK cell adhesion and cytotoxicity through CD2, but not LFA-1 |
| Q41201388 | Amplification of Epstein-Barr virus genomic sequences in blood cells, lacrimal glands, and tears from primary Sjögren's syndrome patients |
| Q29619728 | Biology of natural killer cells |
| Q24799074 | CAM and NK Cells |
| Q45798932 | Cell-mediated immunity to Epstein-Barr virus (EBV) and natural killer (NK)-cell activity in the X-linked lymphoproliferative syndrome |
| Q24655026 | Cloning and chromosomal assignment of a human cDNA encoding a T cell- and natural killer cell-specific trypsin-like serine protease |
| Q40875316 | Common cancers--immunotherapy and multidisciplinary therapy: Parts III and IV. |
| Q41833202 | Defective control of Epstein-Barr virus-infected B cell growth in patients with X-linked lymphoproliferative disease |
| Q40327589 | Depressed immunity and the development of cancer. |
| Q67994739 | Depression and reduced natural killer cytotoxicity: a longitudinal study of depressed patients and control subjects |
| Q41825001 | Detection of X-linked lymphoproliferative disease using molecular and immunovirologic markers |
| Q45798082 | Elevated antibody titers to Epstein-Barr virus and low natural killer cell activity in patients with Chediak-Higashi syndrome |
| Q70190345 | Epstein-Barr serology in immunodeficiencies: an attempt to correlate with immune abnormalities in Wiskott-Aldrich and Chediak-Higashi syndromes and ataxia telangiectasia |
| Q33650107 | Epstein-Barr virus BARF1 protein is dispensable for B-cell transformation and inhibits alpha interferon secretion from mononuclear cells. |
| Q45798742 | Epstein-barr virus (EBV)-induced lymphoproliferative disease in cotton-topped marmosets |
| Q40126396 | Epstein-barr virus and human disease: Immune responses determine the clinical and pathologic expression |
| Q35885953 | Experimental models of lymphoproliferative disease. The mouse as a model for human non-Hodgkin's lymphomas and related leukemias |
| Q72759566 | Further studies of natural killer cell function in Chediak-Higashi patients |
| Q24675226 | Human dendritic cells activate resting natural killer (NK) cells and are recognized via the NKp30 receptor by activated NK cells |
| Q39097082 | Human immunity against EBV-lessons from the clinic. |
| Q35035745 | Human natural killer cell deficiencies and susceptibility to infection |
| Q45844384 | Immune function in chronic active Epstein-Barr virus infection |
| Q39477632 | Immune surveillance and natural resistance: an evaluation |
| Q35885589 | Immunopathology of B-cell lymphomas induced in C57BL/6 mice by dualtropic murine leukemia virus (MuLV) |
| Q41552231 | Immunopathology of the X-Linked Lymphoproliferative Syndrome |
| Q36990044 | Impaired culture generated cytotoxicity with preservation of spontaneous natural killer-cell activity in cartilage-hair hypoplasia |
| Q41704036 | In vitro enhancement of natural killer cell activity against herpesvirus-infected targets in patients with acute lymphocytic leukemia |
| Q37923353 | Insights into NK cell biology from human genetics and disease associations. |
| Q52004511 | Loss of circulating CD27+ memory B cells and CCR4+ T cells occurring in association with elevated EBV loads in XLP patients surviving primary EBV infection |
| Q70160073 | Lymphocyte abnormalities in preleukemia — I. Decreased NK activity, anomalous immunoregulatory cell subsets and deficient EBV receptors |
| Q40127412 | Malignant lymphoproliferative diseases induced by Epstein-Barr virus in immunodeficient patients, including X-linked, cytogenetic, and familial syndromes |
| Q92544064 | Mast Cells and Natural Killer Cells-A Potentially Critical Interaction |
| Q40132201 | Mechanisms of Viral Tumorigenesis |
| Q35096711 | Molecular and immunological basis of X-linked lymphoproliferative disease |
| Q37739485 | Molecular checkpoints controlling natural killer cell activation and their modulation for cancer immunotherapy |
| Q34070452 | Molecular pathogenesis of EBV susceptibility in XLP as revealed by analysis of female carriers with heterozygous expression of SAP. |
| Q38676458 | NK cells and cancer: you can teach innate cells new tricks. |
| Q35019869 | NK cells, innate immunity and hepatitis C infection after liver transplantation |
| Q40101876 | Natural Cell-Mediated Immunity During Viral Infections |
| Q33928216 | Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population |
| Q40105067 | Natural killer cells in resistance to virus-infected cells |
| Q50204340 | Natural killer cells unleashed: Checkpoint receptor blockade and BiKE/TriKE utilization in NK-mediated anti-tumor immunotherapy |
| Q72779539 | Nature of natural killer cell hyporesponsiveness in the Chediak-Higashi syndrome |
| Q72711373 | Normalized natural killer (NK) cell activity in long-term remission of acute leukaemia |
| Q59548366 | Partial albinism with immunodeficiency (Griscelli syndrome) |
| Q41714354 | Partial albinism with immunodeficiency: Griscelli syndrome: report of a case and review of the literature |
| Q93517466 | Polyclonal proliferation of activated suppressor/cytotoxic T cells with transient depression of natural killer cell function in acute infectious mononucleosis |
| Q39483678 | Regulation of hematopoiesis by T lymphocytes and natural killer cells |
| Q72351760 | Retinal necrosis in X-linked lymphoproliferative disease |
| Q48208098 | SAP and Lessons Learned from a Primary Immunodeficiency. |
| Q72815573 | Severe combined immunodeficiency with natural killer-cell predominance: Abrogation of graft-versus-host disease and immunologic reconstitution with HLA-identical bone marrow cells |
| Q24535874 | Structural basis for the interaction of the free SH2 domain EAT-2 with SLAM receptors in hematopoietic cells |
| Q52142276 | Studies of EBV-lymphoid cell interactions in two patients with the X-linked lymphoproliferative syndrome: normal EBV-specific HLA-restricted cytotoxicity. |
| Q37008439 | Studies of the function of natural killer-interferon system in patients with Sjögren syndrome |
| Q45840009 | Successful treatment of chronic active Epstein-Barr virus infection with recombinant interleukin-2. |
| Q92615075 | Targeting natural killer cells in solid tumors |
| Q43991331 | The X-linked lymphoproliferative disease gene product SAP is expressed in activated T and NK cells. |
| Q40131890 | The biology of the human natural killer cell |
| Q40102342 | The clinical value of interferons as antitumor agents |
| Q43769941 | The effects of a Chinese herb formula, anti-cancer number one (ACNO), on NK cell activity and tumor metastasis in rats |
| Q67707509 | The mechanism of action of a synthetic immunomodulator, 3,6-Bis(2-piperidinoethoxy)acridine trihydrochloride (CL 246, 738), in natural killer cell activation in animals |
| Q70425853 | The occurrence of cancer in immune deficiencies |
| Q37811046 | The role of SAP and SLAM family molecules in the humoral immune response |
| Q38478878 | Therapeutic potential and challenges of natural killer cells in treatment of solid tumors |
| Q45800068 | Treatment of life-threatening Epstein-Barr virus infections with acyclovir |
| Q39822208 | Tumor cells do not arise frequently |
| Q70165756 | Viral infections in immunocompromised patients |
| Q52579140 | X-Linked Lymphoproliferative Disease Type 1: A Clinical and Molecular Perspective. |
| Q36464546 | X-linked lymphoproliferative disease (XLP) as a model of Epstein-Barr virus-induced immunopathology |
| Q34775638 | X-linked lymphoproliferative disease: genetic lesions and clinical consequences |
| Q36990192 | X-linked lymphoproliferative syndrome. Natural history of the immunodeficiency |
| Q38236177 | XLP: clinical features and molecular etiology due to mutations in SH2D1A encoding SAP. |
Search more.